Trump has begun another trade war. Here's a timeline of how we got here
Canada's leader laments lost friendship with US in town that sheltered stranded Americans after 9/11
Chinese EV giant BYD's fourth-quarter profit leaps 73%
You're an American in another land? Prepare to talk about the why and how of Trump 2.0
Chalk talk: Star power, top teams and No. 5 seeds headline the women's March Madness Sweet 16
Purdue returns to Sweet 16 with 76-62 win over McNeese in March Madness
ZURICH (Reuters) - Swiss contract drug manufacturer Lonza said on Wednesday it has signed an agreement to acquire the Genentech manufacturing facility in Vacaville, California, from drugmaker Roche for $1.2 billion in cash.
Lonza plans to invest around 500 million Swiss francs ($562.30 million) to upgrade the facility and enhance capabilities at the site to accommodate the next generation of mammalian biologics therapies, the company said in a statement.
($1 = 0.8892 Swiss francs)
(Reporting by Dave Graham; Editing by Miranda Murray)
